Transparent

Robert Nowinski

Name

Robert Nowinski

Location

New York

Bio

Robert Nowinski, a scientist with a doctorate in immunology and a flair for creating new businesses, has combined those talents to found six biotec... (More) Robert Nowinski, a scientist with a doctorate in immunology and a flair for creating new businesses, has combined those talents to found six biotechnology companies. Four of these companies were eventually taken public, and several were acquired by larger corporations. In each business, Robert Nowinski determined the direction, acquired the initial technology, recruited key management and provided oversight for the research programs. Robert Nowinski also ensured the continuing health of the companies by conducting private and public financings of up to $130 million for each one.Education and Early Career MovesRobert Nowinski received his Ph.D. in immunology from the Sloan-Kettering Institute in 1971. From 1971 to 1975 he was an assistant professor of oncology at the University of Wisconsin, after which he served as associate professor of microbiology and immunology at the University of Washington through 1981. Dr. Robert Nowinski also was a founding scientist and head of the Virology Program of the Fred Hutchinson Cancer Research Center in Seattle. His academic research focused on cancer-causing retroviruses, antibody treatments for cancer and antibodies for the diagnosis of sexually-transmitted diseases.Genetic Systems Corp.In 1981, Dr. Robert Nowinski began a second career in the biotechnology industry when he founded Genetic Systems Corp., Seattle. Genetic Systems conducted an IPO financing within one month of its formation. The company developed diagnostic products and treatments for infectious diseases and cancer. From 1981 through 1985, Dr. Robert Nowinski was the company’s chairman and CEO.Genetic Systems developed the first rapid test for Chlamydia, the most prevalent sexually-transmitted disease in humans. This test decreased the average time of diagnosis from 21 days to 45 minutes, lowered the cost of diagnosis from $150 to $4.50 and expanded the U.S. market from 150,000 tests per year to an estimated 20 million. In collaboration with the Institut Pasteur, Genetic Systems then developed the most accurate blood test for HIV within the first generation of HIV diagnostics. Oncogen LPIn 1983, within the structure of Genetic Systems, Dr. Robert Nowinski founded the subsidiary Oncogen LP, dedicated solely to cancer diagnostics. Oncogen, located in the Genetic Systems building, was co-owned and solely financed by Syntex Corp. In 1985, Genetic Systems and Syntex each sold one-third of their interests to Bristol-Myers Corp. and the mandate of Oncogen was expanded to include cancer therapeutics. In 1986, Dr. Robert Nowinski initiated and managed the merger of Genetic Systems and Oncogen LP into Bristol-Myers through a pooling of interests valued at $310 million. Dr. Robert Nowinski was appointed corporate vice president for new technology at Bristol-Myers and chairman of the new Genetic Systems Division. Icos Corp.In 1989, Dr. Robert Nowinski foundedIcos Corp. based in Seattle. Dr. Robert Nowinski served as CEO of Icos from 1989 to 1991. In 1991, he brought Icos public. The company focused on inflammation and novel methods for drug discovery. Icos developed the drug Cialis for treating erectile dysfunction. Eli Lilly markets Cialis, with annual sales exceeding $1.2 billion. In 2006, Icos was acquired by Eli Lilly for $2.2 billion.PathoGenesisIn 1992, Dr. Robert Nowinski founded PathoGenesis, a Seattle company focused on the cause and treatment of chronic illnesses. Dr. Robert Nowinski served as chairman of PathoGenesis from 1992 to 1995. In 1993, he brought PathoGenesis public. In 1997, PathoGenesis received FDA approval to market an aerosolized form of tobramycin, or TOBI, for treating cystic fibrosis. In addition, research within PathoGenesis identified HerpesVirus 6 as a primary causative agent of multiple sclerosis. In 2000, PathoGenesis was acquired by Chiron Corp. for $660 million. TOBI is now the leading treatment for cystic fibrosis; annual sales exceed $600 million. VaxGenIn 1995, Dr. Robert Nowinski founded VaxGen, a South San Francisco, Calif.-based company that develops preventive vaccines for infectious diseases such as HIV, anthrax and smallpox. Dr. Robert Nowinski was VaxGen’s Chairman and CEO and brought the Company public in 1998. Primal Inc.In 2000, Dr. Robert Nowinski founded Primal Inc. Primal, based in Seattle, develops products for behavioral disorders, including those that address disorders in appetite, sexuality, mood, pain and addiction. The company focuses on gene knock-out technology in mice and the biology of G-protein coupled receptors (GPCRs), the targets for over 45% of today’s pharmaceuticals. Primal was co-founded with Dr. Linda Buck, the winner of the 2005 Nobel Prize for Medicine. Primal was the first to describe the full complement of 475 GPCR genes in humans and has within its patent portfolio claims for the entire family of GPCRs as potential drug targets. Primal currently develops new drugs to GPCRs.In 2008, Dr. Robert Nowinski founded ContraFect Corporation in New York City.Robert Nowinski at ZoominfoRobert Nowinski at robertnowinski.comRobert Nowinski at ZiggsRobert Nowinski at robertnowinski.orgRobert Nowinski at robertnowinski.net (Less)

Age

59

Gender

Male

Occupation

Scientist, ContraFect Corporation

Send Robert Nowinski a message

0 documents

Subscribers (0)

Subscribed To (0)

Transparent